Similarities and differences between pediatric and adult nonalcoholic fatty liver disease

Metabolism: Clinical and Experimental

Volumn 65, Issue 8, 2016, Pages 1161-1171

  Crespo, Maricruz ^a   Lappe, Sara ^b   Feldstein, Ariel E ^c   Alkhouri, Naim ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Children; Liver fibrosis; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Noninvasive diagnosis

Indexed keywords

ALPHA TOCOPHEROL; PIOGLITAZONE; PLACEBO;

ADULT; ADULT DISEASE; ARTICLE; CHILD; CHILD NUTRITION; CHILDHOOD DISEASE; CLINICAL FEATURE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LIVER FIBROSIS; MEDICAL HISTORY; MULTICENTER STUDY (TOPIC); NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STEATOSIS; WEIGHT REDUCTION; AGE; DISEASE COURSE; FATTY LIVER; FIBROSIS; INFLAMMATION; LIFESTYLE; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

ADULT; AGE FACTORS; CHILD; DISEASE PROGRESSION; FATTY LIVER; FIBROSIS; HUMANS; INFLAMMATION; LIFE STYLE; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84959571598     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2016.01.008     Document Type: Article

References (83)

1. [1] Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol 107:6 (2012), 811–826, 10.1038/ajg.2012.128 [PubMed PMID: 22641309].
2. [2] Burt, A.D., Lackner, C., Tiniakos, D.G., Diagnosis and Assessment of NAFLD: Definitions and Histopathological Classification. Semin Liver Dis 35:3 (2015), 207–220, 10.1055/s-0035-1562942 Epub 2015/09/18, PubMed PMID: 26378639.
3. [3] Ludwig, J., Viggiano, T.R., McGill, D.B., Oh, B.J., Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55:7 (1980), 434–438 [PubMed PMID: 7382552].
4. [4] Moran, J.R., Ghishan, F.K., Halter, S.A., Greene, H.L., Steatohepatitis in obese children: a cause of chronic liver dysfunction. Am J Gastroenterol 78:6 (1983), 374–377 [PubMed PMID: 6859017].
5. [5] Masarone, M., Federico, A., Abenavoli, L., Loguercio, C., Persico, M., Non alcoholic fatty liver: epidemiology and natural history. Rev Recent Clin Trials 9:3 (2014), 126–133 [PubMed PMID: 25514916].
6. [6] non-alcoholic fatty liver disease study group dttmoPPL, Lonardo, A., Bellentani, S., CK, Argo, Ballestri, S., Byrne, C.D., et al. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis 47:12 (2015), 997–1006, 10.1016/j.dld.2015.08.004 [PubMed PMID: 26454786].
7. [7] Schwimmer, J.B., Deutsch, R., Kahen, T., Lavine, J.E., Stanley, C., Behling, C., Prevalence of fatty liver in children and adolescents. Pediatrics 118:4 (2006), 1388–1393 [PubMed PMID: 17015527].
8. [8] Welsh, J.A., Karpen, S., Vos, M.B., Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. J Pediatr 162:3 (2013), 496–500 e1, 10.1016/j.jpeds.2012.08.043 [PubMed PMID: 23084707; PubMed Central PMCID: PMC3649872].
9. [9] Finkelstein, E.A., Graham, W.C., Malhotra, R., Lifetime direct medical costs of childhood obesity. Pediatrics 133:5 (2014), 854–862, 10.1542/peds.2014-0063 [PubMed PMID: 24709935].
10. [10] Aggarwal, A., Puri, K., Thangada, S., Zein, N., Alkhouri, N., Nonalcoholic Fatty Liver Disease In Children: Recent Practice Guidelines, Where Do They Take Us?. Current pediatric reviews, Volume 10, (4 Issues), 2014, 151–161.
11. [11] Schwimmer, J.B., Pardee, P.E., Lavine, J.E., Blumkin, A.K., Cook, S., Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation 118:3 (2008), 277–283 [PubMed PMID: 18591439].
12. [12] Santoro, N., Caprio, S., Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in obese adolescents: a looming marker of cardiac dysfunction. Hepatology 59:2 (2014), 372–374, 10.1002/hep.26663 [PubMed PMID: 23913480].
13. [13] Lonardo, A., Ballestri, S., Marchesini, G., Angulo, P., Loria, P., Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis 47:3 (2015), 181–190, 10.1016/j.dld.2014.09.020 [PubMed PMID: 25739820].
14. [14] Michaliszyn, S.F., Lee, S., Tfayli, H., Arslanian, S., Polycystic ovary syndrome and nonalcoholic fatty liver in obese adolescents: association with metabolic risk profile. Fertil Steril 100:6 (2013), 1745–1751, 10.1016/j.fertnstert.2013.08.015 [PubMed PMID: 24034940; PubMed Central PMCID: PMC3844059].
15. [15] Targher, G., Rossini, M., Lonardo, A., Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?. Endocrine, 2015, 10.1007/s12020-015-0640-8 [PubMed PMID: 26024975].
16. [16] Adams, L.A., Feldstein, A., Lindor, K.D., Angulo, P., Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology. 39:4 (2004), 909–914 [PubMed PMID: 15057893].
17. [17] Sundaram, S.S., Sokol, R.J., Capocelli, K.E., Pan, Z., Sullivan, J.S., Robbins, K., et al. Obstructive sleep apnea and hypoxemia are associated with advanced liver histology in pediatric nonalcoholic fatty liver disease. J Pediatr 164:4 (2014), 699–706, 10.1016/j.jpeds.2013.10.072 e1 [PubMed PMID: 24321532; PubMed Central PMCID: PMC4014349].
18. [18] van der Voort, E.A., Koehler, E.M., Dowlatshahi, E.A., Hofman, A., Stricker, B.H., Janssen, H.L., et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study. J Am Acad Dermatol 70:3 (2014), 517–524, 10.1016/j.jaad.2013.10.044 [PubMed PMID: 24373781].
19. [19] Angulo, P., Kleiner, D.E., Dam-Larsen, S., Adams, L.A., Bjornsson, E.S., Charatcharoenwitthaya, P., et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 149(2), 2015, 389-+, 10.1053/j.gastro.2015.04.043 [PubMed PMID: WOS:000358429600032].
20. [20] Charlton, M.R., Burns, J.M., Pedersen, R.A., Watt, K.D., Heimbach, J.K., Dierkhising, R.A., Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141:4 (2011), 1249–1253, 10.1053/j.gastro.2011.06.061 [PubMed PMID: 21726509].
21. [21] Wong, R.J., Cheung, R., Ahmed, A., Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 59:6 (2014), 2188–2195, 10.1002/hep.26986 [PubMed PMID: 24375711].
22. [22] Ascha, M.S., Hanouneh, I.A., Lopez, R., Tamimi, T.A., Feldstein, A.F., Zein, N.N., The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51:6 (2010), 1972–1978 [PubMed PMID: 20209604].
23. [23] Welzel, T.M., Graubard, B.I., Quraishi, S., Zeuzem, S., Davila, J.A., El-Serag, H.B., et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol 108:8 (2013), 1314–1321, 10.1038/ajg.2013.160 [PubMed PMID: 23752878; PubMed Central PMCID: PMC4105976].
24. [24] Molleston, J.P., White, F., Teckman, J., Fitzgerald, J.F., Obese children with steatohepatitis can develop cirrhosis in childhood. Am J Geriatr Cardiol 97:9 (2002), 2460–2462 [PubMed PMID: 12358273].
25. [25] Nobili, V., Alisi, A., Grimaldi, C., Liccardo, D., Francalanci, P., Monti, L., et al. Non-alcoholic fatty liver disease and hepatocellular carcinoma in a 7-year-old obese boy: coincidence or comorbidity?. Pediatr Obes 9:5 (2014), e99–e102, 10.1111/j.2047-6310.2013.00209.x [PubMed PMID: 24302697].
26. [26] Feldstein, A.E., Charatcharoenwitthaya, P., Treeprasertsuk, S., Benson, J.T., Enders, F.B., Angulo, P., The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 58:11 (2009), 1538–1544 [PubMed PMID: 19625277].
27. [27] Lonardo, A., Sookoian, S., Chonchol, M., Loria, P., Targher, G., Cardiovascular and systemic risk in nonalcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD. Curr Pharm Des 19:29 (2013), 5177–5192 [PubMed PMID: 23432668].
28. [28] Adams, L.A., Waters, O.R., Knuiman, M.W., Elliott, R.R., Olynyk, J.K., NAFLD as a Risk Factor for the Development of Diabetes and the Metabolic Syndrome: An Eleven-Year Follow-up Study. Am J Gastroenterol 104:4 (2009), 861–867.
29. [29] Baskar, S., Jhaveri, S., Alkhouri, N., Cardiovascular risk in pediatric nonalcoholic fatty liver disease: recent advances. J Clin Lipidol 10:4 (2015), 351–362.
30. [30] Day, C.P., James OF, Steatohepatitis: a tale of two "hits"?. Gastroenterology 114:4 (1998), 842–845 [PubMed PMID: 9547102].
31. [31] Yamaguchi, K., Yang, L., McCall, S., Huang, J., Yu, X.X., Pandey, S.K., et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45:6 (2007), 1366–1374 [PubMed PMID: 17476695].
32. [32] Nobili, V., Svegliati-Baroni, G., Alisi, A., Miele, L., Valenti, L., Vajro, P., A 360-degree overview of paediatric NAFLD: recent insights. J Hepatol 58:6 (2013), 1218–1229, 10.1016/j.jhep.2012.12.003 [PubMed PMID: 23238106].
33. [33] Tilg, H., Moschen, A.R., Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52:5 (2010), 1836–1846, 10.1002/hep.24001 [PubMed PMID: 21038418].
34. [34] Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49:6 (2009), 1877–1887, 10.1002/hep.22848 [PubMed PMID: 19291785].
35. [35] Marra, F., Bertolani, C., Adipokines in liver diseases. Hepatology 50:3 (2009), 957–969, 10.1002/hep.23046 [PubMed PMID: 19585655].
36. [36] Alkhouri, N., Carter-Kent, C., Feldstein, A.E., Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert Rev Gastroenterol Hepatol 5:2 (2011), 201–212 [PubMed PMID: 21476915].
37. [37] Wree, A., Broderick, L., Canbay, A., Hoffman, H.M., Feldstein, A.E., From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol 10:11 (2013), 627–636, 10.1038/nrgastro.2013.149 [PubMed PMID: 23958599].
38. [38] Loomba, R., Schork, N., Chen, C.H., Bettencourt, R., Bhatt, A., Ang, B., et al. Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study. Gastroenterology 149:7 (2015), 1784–1793, 10.1053/j.gastro.2015.08.011 [PubMed PMID: 26299412].
39. [39] Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L.A., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40:12 (2008), 1461–1465 [PubMed PMID: 18820647].
40. [40] Valenti, L., Alisi, A., Galmozzi, E., Bartuli, A., Del Menico, B., Alterio, A., et al. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 52:4 (2010), 1274–1280, 10.1002/hep.23823 [Epub 2010/07/22 PubMed PMID: 20648474].
41. [41] Santoro, N., Feldstein, A.E., Enoksson, E., Pierpont, B., Kursawe, R., Kim, G., et al. The association between hepatic fat content and liver injury in obese children and adolescents: effects of ethnicity, insulin resistance, and common gene variants. Diabetes Care 36:5 (2013), 1353–1360, 10.2337/dc12-1791 [PubMed PMID: 23275357; PubMed Central PMCID: PMC3631865].
42. [42] Santoro, N., Savoye, M., Kim, G., Marotto, K., Shaw, M.M., Pierpont, B., et al. Hepatic fat accumulation is modulated by the interaction between the rs738409 variant in the PNPLA3 gene and the dietary omega6/omega3 PUFA intake. PLoS One, 7(5), 2012, e37827, 10.1371/journal.pone.0037827 [PubMed PMID: 22629460; PubMed Central PMCID: PMC3357343].
43. [43] Molleston, J.P., Schwimmer, J.B., Yates, K.P., KF, Murray, Cummings, O.W., Lavine, J.E., et al. Histological Abnormalities in Children with Nonalcoholic Fatty Liver Disease and Normal or Mildly Elevated Alanine Aminotransferase Levels. J Pediatr, 2014 [PubMed PMID: 24360992].
44. [44] Schwimmer, J.B., Behling, C., Newbury, R., Deutsch, R., Nievergelt, C., Schork, N.J., et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 42:3 (2005), 641–649 [PubMed PMID: 16116629].
45. [45] Carter-Kent, C., Yerian, L.M., Brunt, E.M., Angulo, P., Kohli, R., Ling, S.C., et al. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology 50:4 (2009), 1113–1120 [PubMed PMID: 19637190].
46. [46] Nobili, V., Marcellini, M., Devito, R., Ciampalini, P., Piemonte, F., Comparcola, D., et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology 44:2 (2006), 458–465 [PubMed PMID: 16871574].
47. [47] Suzuki, A., Abdelmalek, M.F., Schwimmer, J.B., Lavine, J.E., Scheimann, A.O., Unalp-Arida, A., et al. Association between puberty and features of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 10:7 (2012), 786–794, 10.1016/j.cgh.2012.01.020 [PubMed PMID: 22343513; PubMed Central PMCID: PMC3382041].
48. [48] Barlow, S.E., Expert, C., Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 120:Suppl. 4 (2007), S164–S192, 10.1542/peds.2007-2329C [PubMed PMID: 18055651].
49. [49] Schwimmer, J.B., Dunn, W., Norman, G.J., Pardee, P.E., Middleton, M.S., Kerkar, N., et al. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology 138:4 (2010), 1357–1364 [64 e1-2. PubMed PMID: 20064512].
50. [50] Dasarathy, S., Dasarathy, J., Khiyami, A., Joseph, R., Lopez, R., McCullough, A.J., Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol 51:6 (2009), 1061–1067 [PubMed PMID: 19846234].
51. [51] Karlas, T., Petroff, D., Garnov, N., Bohm, S., Tenckhoff, H., Wittekind, C., et al. Non-Invasive Assessment of Hepatic Steatosis in Patients with NAFLD Using Controlled Attenuation Parameter and 1H-MR Spectroscopy. PLoS One, 9(3), 2014, e91987, 10.1371/journal.pone.0091987 [PubMed PMID: 24637477; PubMed Central PMCID: PMC3956815].
52. [52] Castera, L., Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease. Semin Liver Dis 35:3 (2015), 291–303, 10.1055/s-0035-1562948 [PubMed PMID: 26378645].
53. [53] Lin, S.C., Heba, E., Wolfson, T., Ang, B., Gamst, A., Han, A., et al. Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat Using a New Quantitative Ultrasound Technique. Clin Gastroenterol Hepatol, 13(7), 2015, 133745 e6, 10.1016/j.cgh.2014.11.027 [PubMed PMID: 25478922; PubMed Central PMCID: PMC4454635].
54. [54] Alkhouri, N., Cikach, F., Eng, K., Moses, J., Patel, N., Yan, C., et al. Analysis of breath volatile organic compounds as a noninvasive tool to diagnose nonalcoholic fatty liver disease in children. Eur J Gen Pract 26:1 (2014), 82–87.
55. [55] Alkhouri, N., McCullough, A., Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD. J Gastroenterol Hepatol 8:10 (2012), 661–668.
56. [56] Machado, M.V., Cortez-Pinto, H., Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol 58:5 (2013), 1007–1019, 10.1016/j.jhep.2012.11.021 [PubMed PMID: 23183525].
57. [57] Cusi, K., Chang, Z., Harrison, S., Lomonaco, R., Bril, F., Orsak, B., et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 60:1 (2014), 167–174, 10.1016/j.jhep.2013.07.042 [PubMed PMID: 23973932].
58. [58] Kwok, R., Tse, Y.K., Wong, G.L., Ha, Y., Lee, A.U., Ngu, M.C., et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease–the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther 39:3 (2014), 254–269, 10.1111/apt.12569 [PubMed PMID: 24308774].
59. [59] Adams, L.A., Feldstein, A.E., Non-invasive Diagnosis of Nonalcoholic Fatty Liver and Nonalcoholic Steatohepatitis. J Dig Dis, 2011 [PubMed PMID: 21091933].
60. [60] Wieckowska, A., Zein, N.N., Yerian, L.M., Lopez, A.R., McCullough, A.J., Feldstein, A.E., In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44:1 (2006), 27–33 [PubMed PMID: 16799979].
61. [61] Feldstein, A.E., Alkhouri, N., De Vito, R., Alisi, A., Lopez, R., Nobili, V., Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. Am J Gastroenterol 108:9 (2013), 1526–1531 [PubMed PMID: 23752877].
62. [62] Alkhouri, N., Alisi, A., Okwu, V., Matloob, A., Ferrari, F., Crudele, A., et al. Circulating Soluble Fas and Fas Ligand Levels Are Elevated in Children with Nonalcoholic Steatohepatitis. Dig Dis Sci, 2015, 10.1007/s10620-015-3614-z [Epub 2015/03/13, PubMed PMID: 25764498].
63. [63] Yang, H.R., Kim, H.R., Kim, M.J., Ko, J.S., Seo, J.K., Noninvasive parameters and hepatic fibrosis scores in children with nonalcoholic fatty liver disease. World J Gastroenterol 18:13 (2012), 1525–1530 [PubMed PMID: 22509085].
64. [64] Mansoor, S., Yerian, L., Lopez, R., Kohli, R., Xanthakos, S., Angulo, P., et al. The Evaluation of Hepatic Fibrosis Scores in Children with Nonalcoholic Fatty Liver Disease. Am J Gastroenterol, 108(S1), 2013 [Abstrac 2055].
65. [65] Alkhouri, N., Mansoor, S., Giammaria, P., Liccardo, D., Lopez, R., Nobili, V., The development of the pediatric NAFLD fibrosis score (PNFS) to predict the presence of advanced fibrosis in children with nonalcoholic fatty liver disease. PLoS One, 9(8), 2014, e104558, 10.1371/journal.pone.0104558 [PubMed PMID: 25121514; PubMed Central PMCID: PMC4133235].
66. [66] Nobili, V., Vizzutti, F., Arena, U., Abraldes, J.G., Marra, F., Pietrobattista, A., et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 48:2 (2008), 442–448 [PubMed PMID: 18563842].
67. [67] Xanthakos, S.A., Podberesky, D.J., Serai, S.D., Miles, L., King, E.C., Balistreri, W.F., et al. Use of magnetic resonance elastography to assess hepatic fibrosis in children with chronic liver disease. J Pediatr 164:1 (2014), 186–188, 10.1016/j.jpeds.2013.07.050 [PubMed PMID: 24064151; PubMed Central PMCID: PMC3872246].
68. [68] Hanquinet, S., Rougemont, A.L., Courvoisier, D., Rubbia-Brandt, L., McLin, V., Tempia, M., et al. Acoustic radiation force impulse (ARFI) elastography for the noninvasive diagnosis of liver fibrosis in children. Pediatr Radiol 43:5 (2013), 545–551, 10.1007/s00247-012-2595-8 [PubMed PMID: 23271404].
69. [69] Nobili, V., Manco, M., Devito, R., Di Ciommo, V., Comparcola, D., Sartorelli, M.R., et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 48:1 (2008), 119–128, 10.1002/hep.22336 [PubMed PMID: 18537181].
70. [70] Michalsky, M., Reichard, K., Inge, T., Pratt, J., Lenders, C., American Society for M, et al. ASMBS pediatric committee best practice guidelines. Surg Obes Relat Dis 8:1 (2012), 1–7, 10.1016/j.soard.2011.09.009 [PubMed PMID: 22030146].
71. [71] Inge, T.H., Zeller, M.H., Jenkins, T.M., Helmrath, M., Brandt, M.L., Michalsky, M.P., et al. Perioperative outcomes of adolescents undergoing bariatric surgery: the Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS) study. JAMA Pediatr 168:1 (2014), 47–53, 10.1001/jamapediatrics.2013.4296 [PubMed PMID: 24189578].
72. [72] Lassailly, G., Caiazzo, R., Buob, D., Pigeyre, M., Verkindt, H., Labreuche, J., et al. Bariatric Surgery Reduces Features of Non-alcoholic Steatohepatitis in Morbidly Obese Patients. Gastroenterology, 2015, 10.1053/j.gastro.2015.04.014 [PubMed PMID: 25917783].
73. [73] Sanyal, A.J., Chalasani, N., Kowdley, K.V., McCullough, A., Diehl, A.M., Bass, N.M., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362:18 (2010), 1675–1685 [PubMed PMID: 20427778].
74. [74] Lavine, J.E., Schwimmer, J.B., Van Natta, M.L., Molleston, J.P., Murray, K.F., Rosenthal, P., et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 305:16 (2011), 1659–1668, 10.1001/jama.2011.520 [PubMed PMID: 21521847; PubMed Central PMCID: PMC3110082].
75. [75] Klein, E.A., Thompson, I.M. Jr., Tangen, C.M., Crowley, J.J., Lucia, M.S., Goodman, P.J., et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306:14 (2011), 1549–1556, 10.1001/jama.2011.1437 [PubMed PMID: 21990298; PubMed Central PMCID: PMC4169010].
76. [76] Miller, E.R. III, Pastor-Barriuso, R., Dalal, D., Riemersma, R.A., Appel, L.J., Guallar, E., Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142:1 (2005), 37–46 [PubMed PMID: 15537682].
77. [77] Nobili, V., Bedogni, G., Alisi, A., Pietrobattista, A., Rise, P., Galli, C., et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child 96:4 (2011), 350–353, 10.1136/adc.2010.192401 [PubMed PMID: 21233083].
78. [78] Nobili, V., Alisi, A., Della Corte, C., Rise, P., Galli, C., Agostoni, C., et al. Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. Nutr Metab Cardiovasc Dis 23:11 (2013), 1066–1070, 10.1016/j.numecd.2012.10.010 [PubMed PMID: 23220074].
79. [79] Sanyal, A.J., Abdelmalek, M.F., Suzuki, A., Cummings, O.W., Chojkier, M., No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology, 147(2), 2014, 37784.e1, 10.1053/j.gastro.2014.04.046 [Epub 2014/05/14, PubMed PMID: 24818764].
80. [80] Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., Lavine, J.E., Van Natta, M.L., Abdelmalek, M.F., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385:9972 (2015), 956–965, 10.1016/S0140-6736(14)61933-4 [PubMed PMID: 25468160].
81. [81] Singh, S., Khera, R., Allen, A.M., Murad, M.H., Loomba, R., Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis. Hepatology 62:5 (2015), 1417–1432, 10.1002/hep.27999 [PubMed PMID: 26189925].
82. [82] Xanthakos, S.A., Kohli, R., Treating pediatric nonalcoholic fatty liver disease with cysteamine: is adiponectin the key?. J Pediatr 161:4 (2012), 579–581, 10.1016/j.jpeds.2012.05.052 [PubMed PMID: 22738945].
83. [83] non-alcoholic fatty liver disease study group dttmoPPL, Lonardo, A., Bellentani, S., Argo, C.K., Ballestri, S., CD, Byrne, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis, 2015, 10.1016/j.dld.2015.08.004 [PubMed PMID: 26454786].